top of page
Modified IPSC’s Combating CBI in Alzheimer’s.png
logo.png

Use of iPSCs in Alzheimer’s Disease Brain Inflammation

kisunla-split.webp
kisunla-split.webp
Patrick_McGeer.jpg
Alzheimer's_Ribbon_(Toshiba).webp
Patrick_McGeer.jpg
Tacrine Image (Toshiba).png
Patrick_McGeer.jpg
lecanemab_(Toshiba)_files2.webp
Patrick_McGeer.jpg
Alzheimers_MRI_(Toshiba).webp
Alois_Alzheimer.jpg
Alois_Alzheimer.jpg

History of Alzheimer's Disease

More awareness is drawn to Alzheimer's. The National Alzheimer's Project Act is passed to further research and patient care.

The drug "Tacrine" becomes the first FDA-approved medication for Alzheimer's.

1904

2000s

2020-2023

1993

2010s

Alzheimer's Disease is first described by Dr. Alois Alzheimer.

Brain scans begin to be used to more thoroughly research Alzheimer's. More distinctions are drawn between Alzheimer's and similar diseases. 

The drug "Lecanemab" is created and passed by the FDA to slow Alzheimer's progression.

Current Treatments for CBI

​Donanemab and Lecanemab

  • Targets amyloid plaques

  • Requires regular MRI scans

  • Risk of Amyloid-Related Imaging Abnormalities (ARIAS,) which can cause visual disturbances, seizures, and even death

Transcranial.jpg

Neuromodulation 

  • Still in the research and clinical trials stage and not on actual patients as of now

bottom of page